Scholar Rock Holding Corporation (NASDAQ: SRRK) is a Healthcare company (Biotechnology) with a market capitalization of $5.4B. The Maz Rating grades it against the other companies in its sector.
Scholar Rock Holding Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $44.54, Scholar Rock Holding Corporation trades at 9702.5x sales and 35.6x book value. Over the last twelve months it generated about $560066 of revenue and a net loss of $386M. It runs a gross margin of -8236.0%, an operating margin of -71732.3% and a net margin of -72563.2%. It shows return on equity of -175.3%, return on invested capital of -110.0% and a free cash flow yield of -5.7%. On the balance sheet: a debt-to-equity ratio of 1.20 and a current ratio of 5.41. Over the past 52 weeks the share price ranged from $35.53 to $61.76, with a beta of 0.62.
Scholar Rock Holding Corporation does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 1 Strong Buy, 12 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Scholar Rock Holding Corporation (SRRK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.10% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.54% / 30% · Interest income / Revenue 718.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 3.10% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.54% / 33% · Receivables / Mkt Cap (36m) 0.04% / 49% · Interest income / Revenue 718.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 3.10% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.54% / 33.33% · Receivables / Mkt Cap (24m) 0.04% / 33.33% · Interest income / Revenue 718.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 36.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.8% / 33.33% · Receivables / Avg Assets (4Q) 0.23% / 33.33% · Interest income / Revenue 718.6% / 5% | Fail |
| FTSE | Debt / Total Assets 44.0% / 33.33% · (Cash+ST Inv) / Total Assets 92.7% / 33.33% · (Cash+Recv) / Total Assets 93.3% / 33.33% · Interest income / Revenue 718.6% / 5% | Fail |
No. As of September 2026, Scholar Rock Holding Corporation (SRRK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Scholar Rock Holding Corporation is over the AAOIFI limit on Interest income / Revenue.
About 718.6% of each dividend: Scholar Rock Holding Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.